Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Oct 15, 2015 4:59pm

126 Views

Post# 24195721

RE:ESPR

Entering ESPR at $20-$25 is sure better than $100 to $125 but not as good at $15-20! A lot of change in valuation in the past year influenced by FDA and competitors in the LDL field.

One must keep in mind that they still have long Phase 3 to get through and they are already at over 500 million market cap. How much upside do you expect in the short-term vs. long-term? How much risk are you willing to take? What is the market size for ETC-1002 with all of the statin/ezetimibe/PCSK9 overlap in that space already? I'm not pushing you one way or the other, but just things to think about.

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale